Afuco™ Anti-TGFB2 ADCC Therapeutic Antibody (Lerdelimumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to TGF beta 2. Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-100 |
| Pricing | Inquiry |
| Host | Human |
| Target | TGFB2 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, IP, FC, FuncS, Neut, IF |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |